Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 460,007
  • Shares Outstanding, K 150,329
  • Annual Sales, $ 107,670 K
  • Annual Income, $ -182,020 K
  • 60-Month Beta 1.68
  • Price/Sales 3.61
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade HRTX with:

Options Overview Details

View History
  • Implied Volatility 91.07% ( -3.79%)
  • Historical Volatility 93.49%
  • IV Percentile 33%
  • IV Rank 8.55%
  • IV High 831.40% on 10/19/23
  • IV Low 21.82% on 09/15/23
  • Put/Call Vol Ratio 0.61
  • Today's Volume 607
  • Volume Avg (30-Day) 1,406
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 22,407
  • Open Int (30-Day) 38,864

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.11
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +74.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.30 +28.70%
on 03/12/24
3.22 -8.07%
on 03/13/24
+0.09 (+3.14%)
since 02/16/24
3-Month
1.60 +85.00%
on 12/27/23
3.22 -8.07%
on 03/13/24
+1.22 (+70.11%)
since 12/18/23
52-Week
0.50 +492.00%
on 11/09/23
3.22 -8.07%
on 03/13/24
+0.64 (+27.59%)
since 03/17/23

Most Recent Stories

More News
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 2.96 (-3.27%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 2.96 (-3.27%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 2.96 (-3.27%)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

HRTX : 2.96 (-3.27%)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 2.96 (-3.27%)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 2.96 (-3.27%)
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 2.96 (-3.27%)
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 2.96 (-3.27%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 2.96 (-3.27%)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by...

HRTX : 2.96 (-3.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 3.21
2nd Resistance Point 3.15
1st Resistance Point 3.05
Last Price 2.96
1st Support Level 2.89
2nd Support Level 2.83
3rd Support Level 2.73

See More

52-Week High 3.22
Last Price 2.96
Fibonacci 61.8% 2.18
Fibonacci 50% 1.86
Fibonacci 38.2% 1.54
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar